Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The rapidity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific memory B or T cell response in vaccinated individuals is important for our understanding of immunopathogenesis of coronavirus disease 2019 (COVID-19). We therefore compared the timing of adequate immune responses between the first and booster doses of COVID-19 vaccines in infection-naïve healthcare workers. Methods: We enrolled healthcare workers who received two doses of either the BNT162b2 vaccine or the ChAdOx1 vaccine, all of whom received the BNT162b2 vaccine as the booster (the third) dose. Spike 1 (S1)-immunoglobulin G (IgG) antibodies and interferon gamma producing T cell responses were measured at 0, 7, 14, and 21 days after the first dose, and at 0 and between 2 to 7 days after the booster dose. Results: After the first-dose vaccination, the S1-IgG antibody responses were elicited within 14 days in the BNT162b2 group and within 21 days in the ChAdOx1 group. After the booster dose, the S1-IgG antibody responses were elicited within 5 days in both groups. The SARS-CoV-2-specific T cell responses appeared at 7 days after the first dose and at 4 days after the booster dose. Conclusions: SARS-CoV-2-specific immune responses by memory B cells and T cells may be expected to appear around 4 to 5 days after the booster dose.
Abstract
Background/Aims: The rapidity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific memory B or T cell response in vaccinated individuals is important for our understanding of immunopathogenesis of coronavirus disease 2019 (COVID-19). We therefore compared the timing of adequate immune responses between the first and booster doses of COVID-19 vaccines in infection-naïve healthcare workers. Methods: We enrolled healthcare workers who received two doses of either the BNT162b2 vaccine or the ChAdOx1 vaccine, all of whom received the BNT162b2 vaccine as the booster (the third) dose. Spike 1 (S1)-immunoglobulin G (IgG) antibodies and interferon gamma producing T cell responses were measured at 0, 7, 14, and 21 days after the first dose, and at 0 and between 2 to 7 days after the booster dose. Results: After the first-dose vaccination, the S1-IgG antibody responses were elicited within 14 days in the BNT162b2 group and within 21 days in the ChAdOx1 group. After the booster dose, the S1-IgG antibody responses were elicited within 5 days in both groups. The SARS-CoV-2-specific T cell responses appeared at 7 days after the first dose and at 4 days after the booster dose. Conclusions: SARS-CoV-2-specific immune responses by memory B cells and T cells may be expected to appear around 4 to 5 days after the booster dose.
참고문헌 (17)
- Thompson MG, "Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 vaccines", N Engl J Med, 385, pp.320~329 (2021)
- Tang L, "Asymptomatic and symptomatic SARS-CoV-2 infections after BNT162b2 vaccination in a routinely screened workforce", JAMA, 325, pp.2500~2502 (2021)
- "Fully vaccinated people can shed their masks in most places: U.S. CDC" (2021)[URL]
- Xin H, "Estimating the latent period of coronavirus disease 2019(COVID-19)", Clin Infect Dis, 74, pp.1678~1681 (2022)
- Orenstein W, "Plotkin’s Vaccines" (2017), Elsevier
- 김지연, "Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines", Immune Network, 21(4), pp.1~9 (2021), 대한면역학회[DOI]
- Kim JY, "Immune responses to the Ch AdOx1 nCoV-19 and BNT162b2 vaccines and to natural coronavirus disease 2019 infections over a 3-month period", J Infect Dis, 225, pp.777~784 (2022)
- Feng S, "Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection", Nat Med, 27, pp.2032~2040 (2021)
- Inoue T, "Generation of memory B cells and their reactivation", Immunol Rev, 283, pp.138~149 (2018)
- Levin EG, "Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months", N Engl J Med, 385, pp.e84~ (2021)
- Shrotri M, "Spike-antibody waning after second dose of BNT162b2 or ChAdOx1", Lancet, 398, pp.385~387 (2021)
- Purtha WE, "Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants", J Exp Med, 208, pp.2599~2606 (2011)
- Khurana S, "Heterologous primeboost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization", PLoS One, 9, pp.e95496~ (2014)
- Ochsenbein AF, "Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs", Proc Natl Acad Sci U S A, 97, pp.13263~13268 (2000)
- Aiba Y, "Preferential localization of IgG memory B cells adjacent to contracted germinal centers", Proc Natl Acad Sci U S A, 107, pp.12192~12197 (2010)
- Song JS, "Serial intervals and household transmission of SARS-CoV-2 Omicron variant, South Korea, 2021", Emerg Infect Dis, 28, pp.756~759 (2022)
- . https:, , doi.org, 2022.01.08.22268920, pp.2022, ~